Jiuzhitang Co Ltd

Jiuzhitang released its 2026 interim report, with net profit attributable to the parent company of 250 million yuan, up 74.01% from the same period last year. Total operating revenue was 1.632 billion yuan, up 29.08% year-on-year. Net cash inflow from operating activities was 471 million yuan, up 121.24% year-on-year, marking two consecutive years of growth. The latest gross margin was 59.70%, up 0.35 percentage points year-on-year, also marking two consecutive years of growth. The latest return on equity was 6.80%, up 2.86 percentage points year-on-year. Diluted earnings per share were 0.30 yuan, up 73.98% year-on-year.

Jiuzhitang has released its 2026 half-year performance forecast, expecting attributable net profit of 241 million to 264 million yuan, a year-on-year increase of 67.63% to 83.63%. The company stated that Harbin Jixianglong Biotechnology was consolidated into the financial statements in November 2025 and has performed well during the reporting period, driving net profit growth. The structural optimization and marketing system reform of the original main business segments are gradually showing results, with sales volumes of most products increasing. At the same time, deeper lean management and cost control have improved operational efficiency, leading to overall business performance growth.